MedRhythms宣布 Movive™帕金森病（PD）治疗方案面向退伍军人推出-动脉网

MedRhythms Announces Availability of Movive™ for Parkinson's Disease (PD) for Veterans

CISION 等信源发布 2025-04-02 21:01



可切换为仅中文







PORTLAND, Maine

缅因州波特兰

，

April 2, 2025

2025年4月2日

/PRNewswire/ --

MedRhythms

today announced that Movive

今天宣布了 Movive

™

, the company's neurorehabilitation system to support gait rehabilitation and motor function in adults with Parkinson's disease (PD), is now available for order within the U.S. Department of Veteran Affairs (VA) through the General Services Administration Multiple Award Schedule (GSA MAS), and also the Federal Supply Schedule (FSS)..

，该公司的神经康复系统用于支持帕金森病（PD）成年患者的步态康复和运动功能，现在可以通过美国总务管理局多重授予计划（GSA MAS）以及联邦供应计划（FSS）在美国退伍军人事务部（VA）内订购。

继续阅读

Movive™️ by MedRhythms is a neurorehabilitation system to support gait rehabilitation and motor function in adults living with Parkinson's disease.

Movive™️ by MedRhythms 是一种神经康复系统，旨在支持帕金森病成年患者的步态康复和运动功能。

'A growing number of Veterans face barriers to consistent, effective neurorehabilitation, particularly for gait and motor function,' said

“越来越多的退伍军人面临持续且有效的神经康复障碍，尤其是在步态和运动功能方面，”

Joel Behnke

乔尔·贝恩ке

, Chief Commercial Officer at MedRhythms. 'With Movive, MedRhythms is not only supporting the VA's focus on home-based, Veteran-centered care—we're also expanding access to RAS therapy to help close key gaps in Parkinson's treatment

MedRhythms首席商务官表示：“通过Movive，MedRhythms不仅支持了退伍军人事务部对以家庭为基础、以退伍军人为中心的护理的关注，我们还正在扩大RAS疗法的使用范围，以帮助填补帕金森病治疗中的关键空白。”

。'

Movive is designed to expand access to individualized, progressive, and engaging rhythmic auditory stimulation (RAS) that is autonomously delivered for use in home and community settings. RAS has been studied extensively in PD and is included in many clinical pathways, including the American Physical Therapy Association's (APTA) Clinical Practice Guidelines for Parkinson's Disease (Osborne et al., 2022)..

Movive 旨在扩大个人化、渐进式且引人入胜的节奏听觉刺激 (RAS) 的使用范围，这种刺激可以自主提供，用于家庭和社区环境。RAS 在帕金森病 (PD) 中已经得到了广泛研究，并被纳入许多临床路径，包括美国物理治疗协会 (APTA) 的《帕金森病临床实践指南》（Osborne 等，2022）。

Dr. Alexander Pantelyat, the Co-Founder and Director of the Johns Hopkins Center for Music and Medicine, and Co-Principal Investigator of a recent feasibility study (Zajac et al., 2023) evaluating Movive, highlighted the strong engagement with the therapy: 'Movive delivers Rhythmic Auditory Stimulation (RAS) to individuals with Parkinson's disease in the home using both familiar and newly discovered music across a variety of genres.

约翰·霍普金斯音乐与医学中心的联合创始人兼主任、最近一项评估Movive可行性的研究（Zajic等人，2023年）的联合首席研究员亚历山大·潘特利亚特博士强调了该疗法的高度参与性：“Movive在家中为帕金森病患者提供节奏听觉刺激（RAS），使用多种类型中熟悉和新发现的音乐。”

Impressively, PD participants increased, on average, their daily step count by 28% and their moderate intensity activity by 56% from baseline. A typical PD patient decreases significantly on both of these measures over the course of their disease.'.

令人印象深刻的是，PD参与者平均每天的步数增加了28%，中等强度活动增加了56%。而典型的PD患者在病程中这两项指标都会显著下降。

Dr.

博士

Terry Ellis

特里·埃利斯

, Professor and Chair of the Department of Physical Therapy at

，物理治疗系教授兼主任

Boston University

波士顿大学

, and Principal Investigator on an additional study evaluating Movive (unpublished data on file) continued: 'Movive was also found to improve stride time variability compared to an active control group, exceeding a minimum clinically important difference, and suggesting improvement in automaticity of walking.'.

，以及另一项评估Movive（未发表的数据存档）研究的首席研究员继续说道：“与活性对照组相比，Movive还被发现能改善步幅时间的变异性，超过了最低临床重要差异，表明步行的自动性有所提高。”

MedRhythms and Lovell Government Services build on their previously announced partnership with the launch of Movive.

MedRhythms 和 Lovell 政府服务公司在其先前宣布的合作伙伴关系基础上，推出了 Movive。

Lovell

洛威尔

will serve as Movive's Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor, providing access to all government organizations and Federal healthcare systems, including the Veterans Health Administration (VHA), the Military Health System (MHS), and Indian Health Services (IHS). Movive is listed on the Federal Supply Schedule (FSS) and GSA Advantage federal contracts.

将作为Movive的服务残疾退伍军人所有的小型企业（SDVOSB）供应商，为所有政府组织和联邦医疗系统提供服务，包括退伍军人健康管理局（VHA）、军事卫生系统（MHS）和印第安人健康服务（IHS）。Movive被列入联邦供应计划（FSS）和GSA Advantage联邦合同。

Listing products with .

列出产品。

Lovell

洛弗尔

streamlines the acquisition process and assists government agencies in meeting their SDVOSB procurement goals.

简化了收购流程，并协助政府机构实现其SDVOSB采购目标。

To learn more about Movive, visit:

要了解有关 Movive 的更多信息，请访问：

https://movive.com

For technical specifications or clinical onboarding support, contact:

有关技术规格或临床应用支持，请联系：

sales@movive.com

销售部邮箱：sales@movive.com

April is Parkinson's Disease Awareness Month

四月是帕金森病宣传月。

PD is the fastest growing neurodegenerative disease in the world

帕金森病是世界上增长最快的神经退行性疾病。

. According to the

。根据

Parkinson's Foundation

帕金森基金会

, nearly one million Americans have PD, including 110,000 Veterans, making it the second most common neurodegenerative disease. Gait impairment and loss of motor function are defining symptoms of PD, with walking and mobility as the number one patient-reported challenge.

，近一百万美国人患有帕金森病，其中包括11万名退伍军人，这使得帕金森病成为第二常见的神经退行性疾病。步态障碍和运动功能丧失是帕金森病的标志性症状，而行走和移动是患者报告的首要挑战。

About Lovell Government Services

关于洛弗尔政府服务

Lovell Government Services has been a trusted SDVOSB vendor since 2013 with a proven track record of successfully introducing suppliers to the government market.

自 2013 年以来，Lovell Government Services 一直是一家值得信赖的 SDVOSB 供应商，成功将供应商引入政府市场方面拥有经过验证的记录。

Lovell

洛弗尔

is a three-time Inc. 5000 honoree and leader in the federal space. They partner with medical and pharmaceutical companies looking to better serve Veteran and military patient populations, increase their federal revenue stream, and win government contracts.

是一家三次入选Inc. 5000榜单的获奖者，也是联邦领域的领导者。他们与医疗和制药公司合作，致力于更好地服务退伍军人和军队患者群体，增加联邦收入来源，并赢得政府合同。

Learn more at

了解更多内容，请访问

www.lovellgov.com

About MedRhythms

关于MedRhythms

MedRhythms is pioneering the development of next-generation neurotherapeutics designed to improve walking, mobility and related functional outcomes via a proprietary, patented technology platform. The company's platform combines sensors, software, and music (via a partnership with Universal Music Group) with advanced neuroscience to target neural circuitry.

MedRhythms 正在开创下一代神经治疗技术的开发，旨在通过专有的、获得专利的技术平台改善行走、移动能力及相关功能结果。该公司的平台结合了传感器、软件和音乐（通过与环球音乐集团的合作），并利用先进的神经科学来针对神经回路。

The company is developing a pipeline of digital therapeutics across a range of neurological conditions, including stroke, multiple sclerosis and Parkinson's disease. The company's product for chronic stroke walking deficits received Breakthrough Device Designation in 2020, and the company raised a Series B financing round in 2021 led by Morningside Ventures and Advantage Capital.

公司正在开发一系列针对神经疾病（包括中风、多发性硬化症和帕金森病）的数字疗法。该公司针对慢性中风行走缺陷的产品于2020年获得了突破性设备认定，并在2021年由晨兴创投和优势资本领投了B轮融资。

MedRhythms is headquartered in .

MedRhythms 总部位于。

Portland, Maine

缅因州波特兰市

. For more information,

。欲了解更多信息，

visit www.medrhythms.com

访问 www.medrhythms.com

。

Forward-Looking Statements

前瞻性声明

THIS MANAGEMENT COMMENTARY CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO THE COMPANY THAT ARE BASED ON INFORMATION AVAILABLE TO US AS OF THE DATE HEREOF. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS ABOUT THE COMPANY'S BELIEFS, DESIGNS, ANTICIPATION, AIMS, GOALS, EXPECTATIONS AND POTENTIAL RESULTS ARE FORWARD-LOOKING STATEMENTS.

本管理层评论包含某些前瞻性陈述和关于公司的信息，这些信息基于我们截至本文件日期可获得的信息。非历史事实的陈述，包括关于公司信念、设计、预期、目标、期望和潜在结果的陈述，均为前瞻性陈述。

IN ADDITION, THE WORDS 'WILL,' 'MAY,' 'BELIEVE,' 'ANTICIPATE,' 'INTEND,' 'ESTIMATE,' 'EXPECT,' 'PROJECT,' 'PLAN,' 'SHOULD,' 'COULD,' AND SIMILAR EXPRESSIONS, AND THEIR VARIATIONS AND NEGATIVES, AS THEY RELATE TO THE COMPANY OR THE FUTURE PERFORMANCE OF THE COMPANY, ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS.

此外，与公司或公司未来业绩相关的“将”、“可能”、“相信”、“预期”、“打算”、“估计”、“预计”、“预测”、“计划”、“应该”、“可以”等词语及其变体和否定形式，旨在识别前瞻性陈述。

SUCH FORWARD LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES, ASSUMPTIONS AND OTHER IMPORTANT FACTORS THAT COULD CAUSE THE COMPANY'S ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH FORWARD LOOKING STATEMENTS.

此类前瞻性陈述涉及已知和未知的风险、不确定性、假设及其他重要因素，这些因素可能导致公司的实际结果、业绩或成就与该等前瞻性陈述明示或暗示的任何未来结果、业绩或成就存在重大差异。

THIS MANAGEMENT COMMENTARY SPEAKS ONLY AS OF THE DATE HEREOF AND THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO UPDATE THIS COMMENTARY IN THE FUTURE..

本管理层评论仅代表截至本文发布之日的情况，公司不承担在未来更新本评论的任何义务。

Contact

联系

press@medrhythms.com

SOURCE MedRhythms

来源：MedRhythms

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+